Results 131 to 140 of about 15,946 (160)

Development of a protocol for the quantitative determination of HBeAg using the Elecsys^® HBeAg immunoassay

Journal of Viral Hepatitis, 2010
Summary.  Loss of hepatitis ‘e’ antigen (HBeAg) in patients with HBeAg‐positive chronic hepatitis B is associated with improved long‐term clinical outcome and is defined as a goal of antiviral treatment by clinical practice guidelines. Recent studies suggest that baseline levels and on‐treatment monitoring of HBeAg levels may identify patients most ...
Wursthorn, Karsten, Zacher, Behrend, Jaroszewicz, Jerzy, Darnedde, Martina, Manns, Michael, Wedemeyer, Heiner   +5 more
openaire   +2 more sources

Treatment of HBeAg-Negative Chronic Hepatitis B

Seminars in Liver Disease, 2003
The goals of therapy in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are to abolish or efficiently suppress viral replication, which represents the main determinant of underlying liver necroinflammation and fibrosis. Currently available agents include interferon-alfa (IFN-alpha), lamivudine, and soon adefovir dipivoxil.
Stephanos J, Hadziyannis, George V, Papatheodoridis, Dimitrios, Vassilopoulos   +2 more
openaire   +2 more sources

Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferon

Antiviral Research
HBeAg loss is an important endpoint for antiviral therapy in chronic hepatitis B (CHB), however there are no reliable biomarkers to identify patients who will respond to the addition of pegylated interferon to nucleos(t)ide analogue (NA) therapy.To evaluate the use of serum biomarkers to predict HBeAg loss.HBeAg positive CHB participants on NAs who ...
Daniel Q. Huang, Liang Shen, Wah Wah Phyo, Gavin Cloherty, Emily K. Butler, Mary C. Kuhns, Anne L. McNamara, Vera Holzmayer, Jeffrey Gersch, Mark Anderson, Wei Lyn Yang, Jing Hieng Ngu, Jason Chang, Jessica Tan, Taufique Ahmed, Yock Young Dan, Yin Mei Lee, Guan Huei Lee, Poh Seng Tan, Mark Muthiah, Htet Toe Wai Khine, Chris Lee, Amy Tay, Seng Gee Lim   +23 more
openaire   +2 more sources

Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion

Hepatology International, 2014
It remains unclear whether chronic hepatitis B patients who undergo interferon (IFN)-induced hepatitis B e antigen (HBeAg) seroconversion have a higher risk of hepatitis B virus (HBV) reactivation and HBeAg seroreversion than those with spontaneous HBeAg seroconversion.A total of 80 and 251 non-cirrhotic patients with interferon-induced and spontaneous
Chien-Hung, Chen, Sheng-Nan, Lu, Chuan-Mo, Lee, Chao-Hung, Hung, Jing-Houng, Wang, Tsung-Hui, Hu   +5 more
openaire   +2 more sources

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

Gastroenterology, 2008
The aim of this study was to evaluate the long-term sustainability of response in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B treated with pegylated interferon (PEG-IFN) alpha-2b alone or in combination with lamivudine.All 266 patients enrolled in the HBV99-01 study were offered participation in a long-term follow-up (LTFU)
Buster, Erik, Flink, Hajo, Cakaloglu, Yilmaz, Simon, Krzysztof, Trojan, Jorg, Tabak, Fehmi, So, Thomas, Feinman, S., Mach, Tomasz, Akarca, Ulus, Schutten, Martin, Tielemans, Wanda, Vuuren, Anneke, Hansen, Bettina, Janssen, Harry   +14 more
openaire   +4 more sources

Long‐term effect of maternal HBeAg on delayed HBeAg seroconversion in offspring with chronic hepatitis B infection

Liver International, 2011
Abstract Background and aims: This cohort study investigated the long‐term effect of maternal hepatitis B virus (HBV) sero‐status on the spontaneous HBeAg seroconversion in offspring with chronic HBV infection. Methods: A total of 185 HBeAg‐positive chronic HBV‐infected children, with maternal HBV seromarkers checked, were ...
Yu-Ru, Tseng, Jia-Feng, Wu, Yen-Hsuan, Ni, Huey-Ling, Chen, Chih-Cheng, Chen, Wan-Hsin, Wen, Hong-Yuan, Hsu, Mei-Hwei, Chang   +7 more
openaire   +2 more sources

Differential Intrahepatic Integrated HBV DNA Patterns Between HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B

ABSTRACTBackgroundHBsAg can be derived from intrahepatic cccDNA and integrated HBV DNA (iDNA). We examined the iDNA from liver tissues of 24 HBeAg(+) and 32 HBeAg(−) treatment-naive CHB participants.MethodsLiver tissues were obtained from the North American Hepatitis B Research Network (HBRN). For cccDNA analysis, DNA was heat-denatured and digested by
Daryl T-Y Lau, Elena S Kim, Zhili Wang, Wendy C King, David E Kleiner, Marc G. Ghany, Amanda S Hinerman, Yuanjie Liu, Raymond T. Chung, Richard K Sterling, Gavin Cloherty, Selena Y. Lin, Hsin-Ni Liu, Ying-Hsiu Su, Haitao Guo   +14 more
openaire   +2 more sources

Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B

Gastroenterology, 2009
This study aimed to identify the predictors for early hepatitis B e antigen (HBeAg) seroconversion following acute exacerbation (AE) in patients with HBeAg-positive chronic hepatitis B (CHB).A total of 151 patients with HBeAg-positive CHB and AE were consecutively enrolled. AE was defined as an elevation of alanine aminotransferase level to more than 5
Hyoung Su, Kim, Ha Jung, Kim, Woon Geon, Shin, Kyung Ho, Kim, Jin Heon, Lee, Hak Yang, Kim, Myoung Kuk, Jang   +6 more
openaire   +2 more sources

Stopping Therapy in HBeAg Negative Disease

Current Hepatitis Reports, 2013
Chronic hepatitis B infection confers a major risk of cirrhosis and hepatocellular carcinoma worldwide. The ultimate long-term goal of chronic hepatitis B therapy is to reduce morbidity and mortality related to liver disease progression. The ideal treatment endpoint is HBsAg seroconversion.
Weng Kai Chan, Soek-Siam Tan, Rosmawati Mohamed   +2 more
openaire   +1 more source

Prediction of spontaneous HBeAg seroconversion in HBeAg‐positive chronic hepatitis B patients during the immune clearance phase

Journal of Medical Virology, 2014
Spontaneous hepatitis B virus (HBV) e antigen (HBeAg) seroconversion is associated with reduced risk of liver‐related complications, but is poorly understood. In this study, 113 chronic hepatitis B patients in the immune active HBeAg‐positive phase were followed up for 76 weeks.
Guangjun, Song, Huiying, Rao, Bo, Feng, Lai, Wei   +3 more
openaire   +2 more sources